Using machine learning and metabolism changes to detect pancreatic cancer early
Altered metabolism and machine learning for pancreatic cancer early detection
This study is looking for better ways to spot pancreatic cancer early by using computer technology to analyze medical records and find patients who might be at risk, while also testing new, easy tests from stool samples and scans to catch signs of the disease sooner.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-10909112 on NIH RePORTER |
What this research studies
This research aims to improve the early detection of pancreatic cancer, which is often diagnosed too late for effective treatment. It utilizes machine learning to analyze electronic medical records and identify patients at high risk for pancreatic ductal adenocarcinoma (PDAC). Additionally, the study seeks to develop non-invasive biomarkers from stool samples and CT imaging that can indicate metabolic changes associated with early-stage PDAC. By focusing on these innovative approaches, the research hopes to enhance screening methods and improve patient outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals with a family history of pancreatic cancer, those with pancreatic cystic lesions, or patients with specific genetic predispositions.
Not a fit: Patients with advanced pancreatic cancer who are already diagnosed and undergoing treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to earlier detection of pancreatic cancer, significantly improving survival rates and treatment options for patients.
How similar studies have performed: Other research has shown promise in using machine learning and biomarkers for cancer detection, indicating that this approach could be effective.
Where this research is happening
Boston, United States
- Dana-Farber Cancer Inst — Boston, United States (Active)
Researchers
- Principal investigator: Wolpin, Brian Matthew — Dana-Farber Cancer Inst
- Study coordinator: Wolpin, Brian Matthew
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.